Phaseline

Companies › Gritgen Therapeutics

Gritgen Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GS1191-0445 injection
AAV8-delivered gene therapy expressing B-domain deleted human factor VIII (FVIII)
F8Phase 3Hemophilia A; Severe Hemophilia ANov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06833983GS1191-0445 injectionPhase 3Hemophilia AHematologyNov 2026
NCT07548411GS1191-0445 injectionPhase 1Severe Hemophilia AHematologyDec 2029

Targets

F8 (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech Octapharma ASC Therapeutics Bioverativ, a Sanofi company Biocad Hangzhou Gensciences Biopharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Forma Therapeutics Wuhan Createrna Science and Technology Pharmanutra

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.